The treatment of arterial hypertension with a new alpha-blocker, indoramin
- 1 January 1974
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 2 (8) , 437-443
- https://doi.org/10.1185/03007997409115239
Abstract
Thirty patients with moderate essential hypertension were treated with indoramin, a new alpha-adrenoceptor blocking agent. After 2 weeks on placebo for stabilization of the blood pressure and screening of cases with stable hypertension, treatment was started with 20 mg. t.i.d. Drug was titrated in each patient and the effective dosage was found to be between 150 and 300 mg. per day. Twenty-five patients were followed for 12 weeks, 4 for 11 weeks and 1 for 9 weeks. This last one was the only patient who failed to respond to treatment. The results were considered excellent or good in 25 of the 30 patients. No significant side-effects were recorded. There were no abnormal laboratory findings. Tolerance to standardised excercise appeared to be increased.Keywords
This publication has 8 references indexed in Scilit:
- Clinical evaluation of indoramin, a new antihypertensive agentEuropean Journal of Clinical Pharmacology, 1973
- The evaluation of the α-adrenoceptor blocking action of indoramin, phentolamine and thymoxamine on the rat and guinea-pig isolated mesenteric vasculature and aortic spiral preparationsJournal of Pharmacy and Pharmacology, 1973
- Further evaluation of phentolamine (‘Regitine’) in cardiac arrhythmiasCurrent Medical Research and Opinion, 1973
- Pharmacologic studies of indoramin in manClinical Pharmacology & Therapeutics, 1972
- A comparison of the cardiovascular actions of indoramin, propranolol, lignocaine, and quinidineCardiovascular Research, 1972
- The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901)Journal of Pharmacy and Pharmacology, 1971
- The Paradox of Beta-Adrenergic Blockade in HypertensionCirculation, 1968